Learn / Clinical Research Management / The business of clinical research
Different kinds of studies: vaccines, devices, observational and decentralised trials
13 minute read · 6-question quiz
What you will learn
Describe the particular features of vaccine trials, device trials and observational studies
Explain decentralised and hybrid trial elements and their data quality implications
Identify opportunities and challenges for research in African settings
Not all clinical research looks like a phase III drug trial. A professional needs to recognise how the principles apply across study types.
Vaccine trials
- Participants are often healthy, so tolerance for risk is low and safety standards are very high.
- Large sample sizes are needed for efficacy because disease incidence is low among those vaccinated and unvaccinated.
- Immunogenicity (antibody or cell responses) is used as an endpoint, along with disease occurrence.
- Follow-up includes solicited reactogenicity (diaries of expected local and general reactions in the days after vaccination) and long-term safety.
- Community engagement is crucial, because trials often involve children and entire communities.
Medical device trials
- Devices are regulated differently from drugs: classes by risk, performance and safety endpoints, and sometimes single-arm designs.
- Operator training and learning curves influence results.
- Blinding is often hard, and sham procedures raise ethical questions.
- Standards such as ISO 14155 (Good Clinical Practice for devices) apply.
Observational and real-world studies
- Cohort studies, registries, case-control studies and chart reviews.
- Used for safety (pharmacovigilance), natural history, effectiveness in routine care, and health economics.
- Ethics review is still required, though consent may sometimes be waived for anonymised records under strict conditions.
- Data quality and bias control (confounding, selection) are central.
Decentralised and hybrid trials
Decentralised clinical trials (DCTs) move some or all activities from research sites to participants' homes or local facilities, using tools such as telemedicine, home nursing, wearable devices, electronic consent, and direct-to-participant drug shipment. Hybrid trials combine site visits with decentralised elements.
Benefits: reduced travel, wider and more diverse participation, and better retention. Challenges: data security and privacy, identity verification, equipment and connectivity, supervision of remote procedures, product handling at home, and different rules between countries. Regulators allow these approaches when participant safety and data integrity are maintained.
Research in Africa
Opportunities: high burden of important diseases (malaria, HIV, TB, maternal and neonatal conditions, emerging infections), engaged communities, experienced research institutions and growing regulatory harmonisation.
Challenges: limited infrastructure and cold chain, sometimes lengthy approvals, shortage of trained staff, ethical issues of power and benefit-sharing, and the need for fair partnerships in which local researchers lead and benefit.
Summary
Vaccine, device and observational studies each have distinct risk profiles, endpoints and regulations.
Decentralised and hybrid trials reduce participant burden but need validation, privacy and oversight.
Research in Africa offers high-burden disease questions and strong communities, with infrastructure and equity challenges.
Design should follow the question and setting.
Check your understanding
Draft study guide. Spotted an error or something unclear? Tell us at hello@scintria.com. This is educational material, not clinical or regulatory advice.